In the Literature

The consumption of ultra-processed foods is associated with an increased risk for cancer and cancer-related death, according to findings from a recent study. Read More ›

Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study. Read More ›

In a new study published in the Journal of Managed Care & Specialty Pharmacy, Teresa Gibson, PhD, Professor of Practice, School of Mathematical Sciences, RIT, showed that an individual’s previous adherence behavior is an important predictor of future adherence. Read More ›

According to published results from a phase 3, prospective, multicenter, randomized clinical trial, the addition of the CD-30–targeted antibody–drug conjugate brentuximab vedotin (Adcetris) to standard chemotherapy can reduce the risk for relapse in this population of patients while providing a better tolerability profile. Read More ›

Read More ›

Second-line standard therapy for patients with relapsed or refractory large B-cell lymphoma is high-dose chemotherapy and autologous stem-cell transplantation (ASCT), but the prognosis after first-line therapy is poor for many patients, who are unable to receive definitive therapy. Read More ›

First-line chemotherapy is the standard of care for advanced esophageal SCC, but survival outcomes are poor. First-line combination immunotherapy with the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy) led to longer overall survival (OS) than chemotherapy or nivolumab monotherapy in solid tumors. Read More ›

The number of women screened for cervical cancer in the United States declined between 2005 and 2019, with lack of knowledge about the need for screening cited as the primary reason for not being up to date, according to findings from a recent population-based, cross-sectional study. Read More ›

Nivolumab (Opdivo) has been shown to have antitumor activity in patients with metastatic urothelial carcinoma who received platinum treatment. However, the role of this agent as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma following surgery has been unclear. In a recent study, researchers evaluated the efficacy and safety of adjuvant nivolumab compared with placebo in patients with muscle-invasive urothelial carcinoma following radical surgery (Bajorin DF, et al. N Engl J Med. 2021;384:2102-2104). Read More ›

Sacituzumab govitecan (Trodelvy), a Trop-2 antibody and topoisomerase inhibitor, showed promising results in a small clinical trial of patients with metastatic TNBC. These findings provided the basis for accelerated FDA approval of this agent in April 2020 for the treatment of patients with metastatic TNBC who have received ≥2 previous therapies in the metastatic setting, with full approval contingent on the results of the confirmatory phase 3 ASCENT study (Bardia A, et al. N Engl J Med. Read More ›